-
1Academic Journal
Συγγραφείς: А. А. Черняк
Πηγή: Žurnal Grodnenskogo Gosudarstvennogo Medicinskogo Universiteta, Vol 22, Iss 5, Pp 451-457 (2024)
Θεματικοί όροι: ишемическая болезнь сердца, рестеноз, чрескожное коронарное вмешательство, р-селектин, интегрин-β3, биохимические маркеры, предикторы, Medicine
Περιγραφή αρχείου: electronic resource
Relation: http://journal-grsmu.by/index.php/ojs/article/view/3197; https://doaj.org/toc/2221-8785; https://doaj.org/toc/2413-0109
Σύνδεσμος πρόσβασης: https://doaj.org/article/d037369ac8f3432bb594097d46d701d3
-
2Academic Journal
Συγγραφείς: Lukyanchik Y.D., Chernysheva T.V., Malinina E.I., Gapon L.I., Petelina T.I., Leonovich S.V., Zuyeva Y.V., Lykasova E.A.
Συνεισφορές: 0
Πηγή: Almanac of Clinical Medicine; Vol 53, No 1 (2025); 34-42 ; Альманах клинической медицины; Vol 53, No 1 (2025); 34-42 ; 2587-9294 ; 2072-0505
Θεματικοί όροι: heart rate variability, young athletes, matrix metalloproteinases, highly dynamic sports, 24-hour ECG monitoring, biochemical markers, вариабельность ритма сердца, юные спортсмены, матриксные металлопротеиназы, высокодинамичные виды спорта, холтеровское мониторирование электрокардиограммы, биохимические маркеры
Περιγραφή αρχείου: application/pdf
Relation: https://almclinmed.ru/jour/article/view/17327/1728; https://almclinmed.ru/jour/article/view/17327/1730; https://almclinmed.ru/jour/article/downloadSuppFile/17327/160044; https://almclinmed.ru/jour/article/downloadSuppFile/17327/160045; https://almclinmed.ru/jour/article/downloadSuppFile/17327/160205; https://almclinmed.ru/jour/article/downloadSuppFile/17327/160416; https://almclinmed.ru/jour/article/downloadSuppFile/17327/160417; https://almclinmed.ru/jour/article/downloadSuppFile/17327/160418; https://almclinmed.ru/jour/article/downloadSuppFile/17327/160419; https://almclinmed.ru/jour/article/downloadSuppFile/17327/160420; https://almclinmed.ru/jour/article/downloadSuppFile/17327/160421; https://almclinmed.ru/jour/article/view/17327
-
3Academic Journal
-
4Academic Journal
Συγγραφείς: Protsenko, V.V., Tuz, Ye.V.
Πηγή: TRAUMA; Том 18, № 2 (2017); 128-136
ТРАВМА; Том 18, № 2 (2017); 128-136Θεματικοί όροι: biochemical markers of bone metabolism, bisphosphonates, bone tumors, 03 medical and health sciences, 0302 clinical medicine, биохимические маркеры костного метаболизма, бисфосфонаты, опухоли костей, 3. Good health, біохімічні маркери кісткового метаболізму, бісфосфонати, пухлини кісток
Περιγραφή αρχείου: application/pdf
Σύνδεσμος πρόσβασης: http://trauma.zaslavsky.com.ua/article/view/102571
-
5Academic Journal
Συγγραφείς: Матниёзова , Зайнаб
Πηγή: International Journal of Scientific Pediatrics; Vol. 3 No. 2 (2024): February; 485-488 ; Международный журнал научной педиатрии; Том 3 № 2 (2024): февраля; 485-488 ; Xalqaro ilmiy pediatriya jurnali; Nashr soni. 3 No. 2 (2024): Fevral; 485-488 ; 2181-2926
Θεματικοί όροι: биохимические маркеры печени, респираторные аллергозы, цитокины, biochemical markers of the liver, respiratory allergies, cytokines, gigarning biokimyoviy markerlar, allergozlar respiratori
Περιγραφή αρχείου: application/pdf
Relation: https://ijsp.uz/index.php/journal/article/view/220/182; https://ijsp.uz/index.php/journal/article/view/220
-
6Academic Journal
Συγγραφείς: Filipenko, V.A., Maruschak, A.P., Leontyeva, F.S., Morozenko, D.V.
Πηγή: TRAUMA; Том 19, № 6 (2018); 109-115
ТРАВМА; Том 19, № 6 (2018); 109-115Θεματικοί όροι: 03 medical and health sciences, 0302 clinical medicine, біохімічні маркери, інтерлейкіни, перипротезна інфекція, ендопротезування, кульшові і колінні суглоби, глікопротеїни, хондроїтинсульфати, діагностична чутливість, biochemical markers, interleukins, periprosthetic infection, endoprosthetics, hip and knee joints, glycoproteins, chondroitin sulfates, diagnostic sensitivity, биохимические маркеры, интерлейкины, перипротезная инфекция, эндопротезирование, тазобедренные и коленные суставы, гликопротеины, хондроитинсульфаты, диагностическая чувствительность, 3. Good health
Περιγραφή αρχείου: application/pdf
-
7Academic Journal
Συγγραφείς: Zadorozhna, B.V., Saiko, O.V.
Πηγή: EMERGENCY MEDICINE; № 4.91 (2018); 86-93
МЕДИЦИНА НЕОТЛОЖНЫХ СОСТОЯНИЙ; № 4.91 (2018); 86-93
МЕДИЦИНА НЕВІДКЛАДНИХ СТАНІВ; № 4.91 (2018); 86-93Θεματικοί όροι: cerebral stroke, post-stroke survival rate, blood-brain barrier, vascular endothelium, inflammatory immune response, biochemical markers, церебральный инсульт, постинсультная выживаемость, гематоэнцефалический барьер, сосудистый эндотелий, воспалительный иммунный ответ, биохимические маркеры, 03 medical and health sciences, 0302 clinical medicine, церебральний інсульт, післяінсультна виживаність, гематоенцефалічний бар'єр, судинний ендотелій, запальна імунна відповідь, біохімічні маркери, 3. Good health
Περιγραφή αρχείου: application/pdf
-
8Academic Journal
Πηγή: Стоматология. Эстетика. Инновации. :95-111
Θεματικοί όροι: минеральная плотность костной ткани, костеобразование, метаболизм костной ткани, age, биохимические маркеры костного ремоделирования, bone remodeling biochemical markers, bone tissue metabolism, resorption, возраст, резорбция, 3. Good health, mineral bone tissue density, bone formation
-
9Academic Journal
Συγγραφείς: Ихтиярова , Гулчехра, Тошева, Ирода, Бозоров, Аброр
Πηγή: International Journal of Scientific Pediatrics; Vol. 2 No. 8 (2023): august; 286-295 ; Международный журнал научной педиатрии; Том 2 № 8 (2023): август; 286-295 ; Xalqaro ilmiy pediatriya jurnali; Nashr soni. 2 No. 8 (2023): avgust; 286-295 ; 2181-2926
Θεματικοί όροι: преждевременные роды, инфекции мочевой системы, биохимические маркеры, premature birth, urinary tract infections, biochemical markers, erta tug'ilish, siydik yo'llari infektsiyalari, biokimyoviy belgilar
Περιγραφή αρχείου: application/pdf
Relation: https://ijsp.uz/index.php/journal/article/view/151/112; https://ijsp.uz/index.php/journal/article/view/151
-
10Academic Journal
Συγγραφείς: Гулис, А. И., Субботина, М. А.
Συνεισφορές: Пинчук, П. Ю., науч. рук.
Θεματικοί όροι: alcohol-induced stress, aliphatic alcohols, biochemical marker, dose-dependent effect, алифатические спирты, биохимические маркеры, биохимия животных, дозозависимый эффект, ксенобиотики, лактатдегидрогеназа, метаболический стресс, спиртовой стресс, токсикокинетика
Περιγραφή αρχείου: application/pdf
Relation: 9bc06ce38678e1d890bb12be86dc42ef; https://rep.vsu.by/handle/123456789/48553
Διαθεσιμότητα: https://rep.vsu.by/handle/123456789/48553
-
11Academic Journal
Συγγραφείς: Voitiv, I. I.
Πηγή: Clinical anatomy and operative surgery; Том 18, № 2 (2019); 13-17
Клиническая анатомия и оперативная хирургия; Том 18, № 2 (2019); 13-17
Клінічна анатомія та оперативна хірургія; Том 18, № 2 (2019); 13-17Θεματικοί όροι: недиференційована дисплазія сполучної тканини, неспроможність швів анастомозів, фенотипічні і біохімічні маркери, критерії діагностики, 03 medical and health sciences, 0302 clinical medicine, недифференцированная дисплазия соединительной ткани, несостоятельность швов анастомозов, фенотипические и биохимические маркеры, критерии диагностики, undifferentiated dysplasia of the connective tissue, anastomosis sutures failure, phenotypic and biochemical markers, diagnostic criteri, 3. Good health
Περιγραφή αρχείου: application/pdf
-
12Academic Journal
Συγγραφείς: Antipkin, Yu. G., Znamenska, T. K., Vorobyova, O. V., Kuznetsov, I. E., Dzhenchako, A. A.
Πηγή: Неонатологія, хірургія та перинатальна медицина, Vol 9, Iss 1(31) (2019)
Neonatology, surgery and perinatal medicine; Том 9, № 1(31) (2019): NEONATOLOGY, SURGERY AND PERINATAL MEDICINE; 5-15
Неонатологія, хірургія та перинатальна медицина; Том 9, № 1(31) (2019): НЕОНАТОЛОГІЯ, ХІРУРГІЯ ТА ПЕРИНАТАЛЬНА МЕДИЦИНА; 5-15
Неонатология, хирургия и перинатальная медицина; Том 9, № 1(31) (2019): НЕОНАТОЛОГИЯ, ХИРУРГИЯ И ПЕРИНАТАЛЬНАЯ МЕДИЦИНА; 5-15Θεματικοί όροι: Inherited Metabolic disorders, Expanded Newborn Screening, Tandem Mass spectrometry, Biochemical Markers of Inherited Metabolic Disorders, Reduction of Infant Mortality and Disability, Practical Steps, наследственные болезни обмена веществ, расширенный скрининг новорожденных, тандемная масс-спектрометрия, биохимические маркеры врожденных нарушений обмена, снижение уровня детской смертности и инвалидности, практические шаги, спадкові хвороби обміну речовин, розширений скринінг новонароджених, тандемна мас-спектрометрія, біохімічні маркери вроджених розладів обміну, зниження рівня дитячої смертності та інвалідності, практичні кроки, Gynecology and obstetrics, 16. Peace & justice, Pediatrics, RJ1-570, 3. Good health, RG1-991
Περιγραφή αρχείου: application/pdf
Σύνδεσμος πρόσβασης: http://neonatology.bsmu.edu.ua/article/download/2413-4260.IX.1.31.2019.1/160017
https://doaj.org/article/2f69f1ace22b41cf8363038e7f2d9848
http://neonatology.bsmu.edu.ua/article/view/2413-4260.IX.1.31.2019.1
http://neonatology.bsmu.edu.ua/article/download/2413-4260.IX.1.31.2019.1/160017
http://neonatology.bsmu.edu.ua/article/view/2413-4260.IX.1.31.2019.1 -
13Academic Journal
Πηγή: Ukrainian Journal «Health of Woman»; No. 3(160) (2022): Ukrainian Journal Health of Woman; 36-41
Ukrainian Journal «Health of Woman»; № 3(160) (2022): Ukrainian Journal Health of Woman; 36-41
Український журнал "Здоров'я жінки"; № 3(160) (2022): Український журнал Здоров’я жінки; 36-41Θεματικοί όροι: біохімічні маркери, крупные акушерские синдромы, biochemical markers, great obstetric syndromes, биохимические маркеры, комбінований пренатальний скринінг І триместру, ультразвукове дослідження, великі акушерські синдроми, combined prenatal screening of the first trimester, комбинированный пренатальный скрининг І триместра, ультразвуковое исследование, 3. Good health, ultrasound examination
Περιγραφή αρχείου: application/pdf
Σύνδεσμος πρόσβασης: http://ujhw.med-expert.com.ua/article/view/265243
-
14Academic Journal
Συγγραφείς: O. S. Glotov, A. N. Chernov, A. I. Korobeynikov, R. S. Kalinin, V. V. Tsai, A. Yu. Anisenkova, S. P. Urazov, A. L. Lapidus, S. V. Mosenko, S. G. Shcherbak, О. С. Глотов, А. Н. Чернов, А. И. Коробейников, Р. С. Калинин, В. В. Цай, А. Ю. Анисенкова, С. П. Уразов, А. Л. Лапидус, С. В. Мосенко, С. Г. Щербак
Συνεισφορές: the study was fi nanced from the budget of the St. Petersburg State Budgetary Healthcare Institution “City Hospital No. 40 of the Kurortny Administrative District” and by St. Petersburg State University (grants ID PURE: 75253103 and ID PURE: 73023672), финансирование исследования было проведено из средств бюджета СПб ГБУЗ «Городская больница № 40 Курортного административного района» и грантов из средств СПбГУ – ID PURE: 75253103 и ID PURE 73023672.
Πηγή: Siberian Journal of Clinical and Experimental Medicine; Том 36, № 4 (2021); 132-143 ; Сибирский журнал клинической и экспериментальной медицины; Том 36, № 4 (2021); 132-143 ; 2713-265X ; 2713-2927
Θεματικοί όροι: корреляции, COVID-19 infection, genes, SNP, severity, clinical symptoms, biochemical markers, correlations, инфекция COVID-19, гены, степень тяжести, клинические симптомы, биохимические маркеры
Περιγραφή αρχείου: application/pdf
Relation: https://www.sibjcem.ru/jour/article/view/1298/673; Reported Cases and Deaths by Country or Territory. URL: https://www.worldometers.info/coronavirus/#countries; Nguyen T.T., Pathirana P.N., Nguyen T., Nguyen Q.V.H., Bhatti A., Nguyen D.C. et al. Genomic mutations and changes in protein secondary structure and solvent accessibility of SARS-CoV-2 (COVID-19 virus). Sci. Rep. 2021;11(1):3487. DOI:10.1038/s41598-021-83105-3.; Yin C. Genotyping coronavirus SARS-CoV-2: Methods and implications. Genomics. 2020;112(5):3588‒3596. DOI:10.1016/j.ygeno.2020.04.016.; Toovey O.T.R., Harvey K.N., Bird P.W., Tang J.W.W. Introduction of Brazilian SARS-CoV-2 484K.V2 related variants into the UK. J. Infect. 2021;82(5):e23–e24. DOI:10.1016/j.jinf.2021.01.025.; World Health Organization. SARS-CoV-2 Variants. URL: https://www.who.int/csr/don/31-december-2020-sars-cov2-variants/en/; Zhang W., Davis B.D., Chen S.S., Sincuir Martinez J.M., Plummer J.T., Vail E. Emergence of a novel SARS-CoV-2 variant in southern California. JAMA. 2021;325(13):1324–1326. DOI:10.1001/jama.2021.1612.; Sabino E.C., Buss L.F., Carvalho M.P.S., Prete C.A. Jr., Crispim M.A.E., Fraiji N.A. et al. Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. Lancet. 2021;397(10273):452–455. DOI:10.1016/S0140-6736(21)00183-5.; PANGO lineages. URL: https://cov-lineages.org/lineage_designation.html; Carr E., Bendayan R., Bean D., Stammers M., Wang W., Zhang H. et al. Evaluation and improvement of the National Early Warning Score (NEWS2) for COVID-19: A multi-hospital study. BMC Med. 2021;19(1):23. DOI:10.1186/s12916-020-01893-3; Gene JET RNA Purification Kit. URL: https://www.thermofisher.com/order/catalog/product/K0731; Illumina DNA Prep with Enrichment. Reference Guide. URL: https://support.illumina.com/content/dam/illumina-support/documents/documentation/chemistry_documentation/illumina_prep/illumina-dna-prep-with-enrichment-reference-1000000048041-06.pdf; Patel H., Varona S., Monzón S., Espinosa-Carrasco J., Heuer M.L., Gabernet G. et al. nf-core/viralrecon: nf-core/viralrecon. Zenodo. 2021. DOI:10.5281/zenodo.514625.; Медицинская статистика. URL: https://medstatistic.ru/calculators/calcodds.html; Abe K., Kabe Y., Uchiyama S., Iwasaki Y.W., Ishizu H., Uwamino Y. et al. Pro108Ser mutant of SARS-CoV-2 3CLpro reduces the enzymatic activity and ameliorates COVID-19 severity in Japan. medRxiv. 2020;11(24):20235952. DOI:10.1101/2020.11.24.20235952.; Caccuri F., Zani A., Messali S., Giovanetti M., Bugatti A., Campisi G. et al. A persistently replicating SARS-CoV-2 variant derived from an asymptomatic individual. J. Transl. Med. 2020;18(1):362. DOI:10.1186/s12967-020-02535-1.; Wang R., Chen J., Gao K., Hozumi Y., Yin C., Wei G.W. Analysis of SARS-CoV-2 mutations in the United States suggests presence of four substrains and novel variants. Commun. Biol. 2021;4(1):228. DOI:10.1038/s42003-021-01754-6.; Korber B., Fischer W.M., Gnanakaran S., Yoon H., Theiler J., Abfalterer W. et al. Tracking changes in SARS-CoV-2 spike: Evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020;182(4):812–827.e19.; Shcherbak S.G., Anisenkova A.Y., Mosenko S.V., Glotov O.S., Chernov A.N., Apalko S.V. et al. Basic predictive risk factors for cytokine storms in COVID-19 patients. Front. Immunol. 2021;12:745515. DOI:10.3389/fi mmu.2021.745515.; Myrstad M., Ihle-Hansen H., Tveita A.A., Andersen E.L., Nygård S., Tveit A. et al. National Early Warning Score 2 (NEWS2) on admission predicts severe disease and in-hospital mortality from Covid-19 – a prospective cohort study. Scand. J. Trauma Resusc. Emerg. Med. 2020;28(1):66. DOI:10.1186/s13049-020-00764-3.; King C.S., Sahjwani D., Brown A.W., Feroz S., Cameron P., Osborn E. et al. Outcomes of mechanically ventilated patients with COVID-19 associated respiratory failure. PLoS One. 2020;15(11):e0242651. DOI:10.1371/journal.pone.0242651.; Caricchio R., Gallucci M., Dass C., Zhang X., Gallucci S., Fleece D. et al. Preliminary predictive criteria for COVID-19 cytokine storm. Ann. Rheum. Dis. 2020;0:1–8. DOI:10.1136/annrheumdis-2020-218323.; Yilmaz A., Sabirli R., Seyit M., Ozen M., Oskay A., Cakmak V. et al. Association between laboratory parameters and CT severity in patients infected with Covid-19: A retrospective, observational study. Am. J. Emerg. Med. 2021;42:110–114. DOI:10.1016/j.ajem.2021.01.040.; https://www.sibjcem.ru/jour/article/view/1298
-
15Academic Journal
Συγγραφείς: Morozenko, D. (Dmytro), Dotsenko, R. (Roman), Vashchyk, Y. (Yevheniia), Zakhariev, A. (Andriy), Zemlianskyi, A. (Andrii), Seliukova, N. (Nataliia), Dotsenko, E. (Ekaterina)
Πηγή: ScienceRise: Biological Science
Θεματικοί όροι: glycosaminoglycans, glycoproteins, sialic acids, соединительная ткань, гликозаминогликаны, гликопротеины, сиаловые кислоты, оксипролин, сполучна тканина, біохімічні маркери, дихальна система, глікозаміноглікани, глікопротеїни, сіалові кислоти, дыхательная система, оксипролін, connective tissue, biochemical markers, respiratory system, oxyproline, биохимические маркеры, Indonesia
Περιγραφή αρχείου: application/pdf
-
16Academic Journal
Συγγραφείς: КОМАРОВА, Галина, БАТЫРУ, Григорий, РОТАРЬ, Евгений, БОУНЕГРУ, Сергей, Адамчук, А., КОЖОКАРЬ, Д.
Θεματικοί όροι: Zea mays, кукуруза, тетраплоиды, биохимические маркеры, зеин, электрофорез, проламины, эндосперм, porumb, tetraploizi, markeri biochimici, zeină, electroforeză, prolamine, endosperm
Περιγραφή αρχείου: application/pdf
Διαθεσιμότητα: http://repository.utm.md/handle/5014/29186
-
17Academic Journal
Συγγραφείς: A. M. Beishembaev, А. М. Бейшембаев
Πηγή: Surgery and Oncology; Том 11, № 2 (2021); 44-48 ; Хирургия и онкология; Том 11, № 2 (2021); 44-48 ; 2949-5857
Θεματικοί όροι: биохимические маркеры, biochemical markers
Περιγραφή αρχείου: application/pdf
Relation: https://www.onco-surgery.info/jour/article/view/509/368; Bryk S., Farkkila A., Bützow R. et al. Clinical characteristics and survival of patients with an adult-type ovarian granulosa cell tumor: a 56-year singlecenter experience. Int J Gynecol Cancer 2015;25(1):33–41. DOI:10.1097/IGC.0000000000000304.; Козаченко В.П. Опухоли стромы полового тяжа. Онкогинекология 2015;(4):41–7.; Schneider D.T., Orbach D., Cecchetto G. et al. Ovarian Sertoli–Leydig cell tumours in children and adolescents: an analysis of the European Cooperative Study Group on Pediatric Rare Tumors (EXPeRT). Eur J Cancer 2015;51(4):543–50. DOI:10.1016/j.ejca.2014.11.013.; Seagle B.L., Ann P., Butler S., Shahabi S. Ovarian granulosa cell tumor: A National Cancer Database study. Gynecol Oncol 2017;146(2):285–91. DOI:10.1016/j.ygyno.2017.05.020.; Levin G., Zigron R., Haj-Yahya R. et al. Granulosa cell tumor of ovary: A systematic review of recent evidence. Eur J Obstet Gynecol Reprod Biol 2018;225:57–61. DOI:10.1016/j.ejogrb.2018.04.002.; Färkkilä A., Haltia U.M., Tapper J. et al. Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary. Ann Med 2017;49(5):435–47. DOI:10.1080/07853890.2017.1294760.; Жорданиа К.И., Кержковская Н.С., Паяниди Ю.Г. и др. Гранулезоклеточные опухоли яичника. Диагностика и лечение. Онкогинекология 2014;(2):33–41.; Haltia U.M., Hallamaa M., Tapper J. et al. Roles of human epididymis protein 4, carbohydrate antigen 125, inhibin B and anti-Müllerian hormone in the differential diagnosis and follow-up of ovarian granulosa cell tumors. Gynecol Oncol 2017;144(1):83–9. DOI:10.1016/j.ygyno.2016.11.018.; Fux-Otta C., Szafryk de Mereshian P., López de Corominas M. et al. Hyperandrogenism produced by ovarian tumors in women at different life stages. Rev Fac Cien Med Univ Nac Cordob 2014;71(2):122–6.; Jashnani K.D., Hegde C.V., Munot S.P. Alfa-fetoprotein secreting ovarian sex cord-stromal tumor. Indian J Pathol Microbiol 2013;56(1):54–6. DOI:10.4103/0377-4929.116152.; Horta M., Cunha T.M., Marques R.C., Felix A. Ovarian Sertoli–Leydig cell tumor with heterologous elements of gastrointestinal type associated with elevated serum alpha-fetoprotein level: an unusual case and literature review. J Radiol Case Rep 2014;8(11):30–41. DOI:10.3941/jrcr.v8i11.2272.; Donovan L.E., Brain P.H., Duggan M.A. Isolated luteinizing hormone (LH) elevation in a woman with secondary amenorrhea: a clue to the diagnosis of an inhibin B-producing thecoma and insights into the influence of inhibin B on LH. Fertil Steril 2010;94(3):1097. DOI:10.1016/j.fertnstert.2010.02.016.; Ran S., Yu Q., Deng S., Xu L. Luteinizing hormone elevation in ovarian granulosa cell tumor: a case report and review of the literature. J Ovarian Res. 2017;10(1):30. DOI:10.1186/s13048-017-0327-2. PMID: 28438188; PMCID: PMC5404692.; Li J., Bao R., Peng S., Zhang C. The molecular mechanism of ovarian granulosa cell tumors. J Ovarian Res 2018;11(1):13. DOI:10.1186/s13048-018-0384-1.; Lim D., Oliva E. Ovarian sex cord-stromal tumours: an update in recent molecular advances. Pathology 2018;50(2):178–89. DOI:10.1016/j.pathol.2017.10.008.; Gadducci A., Cosio S., Carpi A. et al. Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother 2004;58(1):24–38. DOI:10.1016/j.biopha.2003.11.003.; Geerts I., Vergote I., Neven P. et al. The role of inhibins B and antimüllerian hormone for diagnosis and follow-up of granulosa cell tumors. Int J Gynecol Cancer 2009;19(5):847–55. DOI:10.1111/IGC.0b013e3181a702d1.; Mom C.H., Engelen M.J., Willemse P.H. Granulosa cell tumors of the ovary: the clinical value of serum inhibin A and B levels in a large single center. Gynecol Oncol 2007;105:365–72. DOI:10.1016/j.ygyno.2006.12.034.; Portuesi R., Loppini A., Mancari R. et al. Role of inhibin B in detecting recurrence of granulosa cell tumors of the ovary in postmenopausal patients. Int J Gynecol Cancer 2021;31(6):893–8. DOI:10.1136/ijgc-2020-002205.; Kurihara S., Hirakawa T., Amada S. et al. Inhibin-producing ovarian granulosa cell tumor as a cause of secondary amenorrhea: case report and review of the literature. J Obstet Gynaecol Res 2004;30(6):439–43. DOI:10.1111/j.1447-0756.2004.00231.x.; Бейшембаев А.М., Любимова Н.В., Кушлинский Д.Н. и др. Гранулезоклеточные опухоли яичников и ингибин В. Бюллетень экспертной биологической медицины 2010;150(11):567–70.; Singh S.A., Dahshan B., Krc R. et al. Radiographic and Tumor Biomarker Response to Radiotherapy for Recurrent Granulosa Cell Tumor of the Ovary. Cureus 2021;13(2):e13154. DOI:10.7759/cureus.13154.; Любимова Н.В., Бейшембаев А.М., Тимофеев Ю.С., Кушлинский Н.Е. Ингибин В при стромально-клеточных опухолях яичников. Успехи молекулярной онкологии 2020;7(1):32–7. DOI:10.17650/2313-805X-2020-7-1-32-37.; Weintraub A., Eldar-Geva T. AntiMullerian hormone (AMH) determinations in the pediatric and adolescent endocrine practice. Pediatr Endocrinol Rev 2017;14(4):364–70. DOI:10.17458/per.vol14.2017.WG.Mullerian.; Chen S., Yang B., Fan J. Diagnostic value of anti-Müllerian hormone in ovarian granulosa cell tumor: A meta-analysis. Eur J Obstet Gynecol Reprod Biol 2020;253:266–72. DOI:10.1016/j.ejogrb.2020.08.011.; Shrikhande L., Shrikhande B., Shrikhande A. AMH and its clinical implications. J Obstet Gynaecol India 2020;70(5):337–41. DOI:10.1007/s13224-020-01362-0.; Chang H.L., Pahlavan N., Halpern E.F., MacLaughlin D.T. Serum Müllerian Inhibiting Substance/anti-Müllerian hormone levels in patients with adult granulosa cell tumors directly correlate with aggregate tumor mass as determined by pathology or radiology. Gynecol Oncol 2009;114(1):57–60. DOI:10.1016/j.ygyno.2009.02.023.; Victoria M., Labrosse J., Krief F. et al. Anti Müllerian hormone: More than a biomarker of female reproductive function. J Gynecol Obstet Hum Reprod 2019;48(1):19–24. DOI:10.1016/j.jogoh.2018.10.015.
-
18Academic Journal
Συγγραφείς: E. Kurtukov A., Yu. Ragino I., Е. Куртуков А., Ю. Рагино И.
Πηγή: Bulletin of Siberian Medicine; Том 20, № 2 (2021); 148-159 ; Бюллетень сибирской медицины; Том 20, № 2 (2021); 148-159 ; 1819-3684 ; 1682-0363 ; 10.20538/1682-0363-2021-20-2
Θεματικοί όροι: chronic obstructive pulmonary disease, chronic bronchitis, biochemical markers, tumor necrosis factor alpha, interleukin 1, interleukin 6, interleukin 8, interleukin 10, tissue factor, type 1 plasminogen activator inhibitor, monocyte chemoattractant protein 1, хронический бронхит, хроническая обструктивная болезнь легких, биохимические маркеры, фактор некроза опухоли альфа, интерлейкин 1, интерлейкин 6, интерлейкин 8, интерлейкин 10, тканевой фактор, ингибитор активатора плазминогена 1-го типа, моноцитарно-хемоаттрактантный протеин 1
Περιγραφή αρχείου: application/pdf
Relation: https://bulletin.tomsk.ru/jour/article/view/4391/2997; https://bulletin.tomsk.ru/jour/article/view/4391/3027; Kim V., Criner G.J. The chronic bronchitis phenotype in chronic obstructive pulmonary disease: Features and implications. Curr. Opin. Pulm. Med. 2015; 21 (2): 133–141. DOI:10.1097/MCP.0000000000000145.; Burgel P.R., Nesme-Meyer P., Chanez P. et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest. 2009; 135 (4): 975–982. DOI:10.1378/CHEST.08-2062.; De Oca M.M., Halbert R.J., Lopez M.V. et al. The chronic bronchitis phenotype in subjects with and without COPD: the PLATINO study. Eur. Respir. J. 2012; 40 (1): 28–36. DOI:10.1183/09031936.00141611.; Martinez C.H., Kim V., Chen Y. et al. The clinical impact of non-obstructive chronic bronchitis in current and former smokers. Respir. Med. 2014; 108 (3): 491–499. DOI:10.1016/J.RMED.2013.11.003.; Lahousse L., Seys L.J.M., Joos G.F., Franco O.H., Stricker B.H., Brusselle G.G. Epidemiology and impact of chronic bronchitis in chronic obstructive pulmonary disease. Eur. Respir. J. 2017; 50 (2): 1–4. DOI:10.1183/13993003.02470-2016.; Lu M., Yao W., Zhong N. et al. Chronic obstructive pulmonary disease in the absence of chronic bronchitis in China. Respirology. 2010; 15 (7): 1072–1078. DOI:10.1111/J.1440-1843.2010.01817.X.; Carbone M., Ly B., Dodson R., Pagano I., Morris P., Dogan U., Gazdar A., Pass H., Yang H. Malignant mesothelioma: facts, myths, and hypotheses. J. Cell Physiol. 2012; 227 (1): 44–58. DOI:10.1002/jcp.22724.; Chu W.M. Tumor necrosis factor. Cancer Lett. 2013; 328 (2): 222–225. DOI:10.1016/j.canlet.2012.10.014.; Swardfager W., Lanctôt K., Rothenburg L., Wong A., Cappell J., Herrmann H. A meta-analysis of cytokines in Alzheimer’s disease. Biol. Psychiatry. 2010; 68 (10): 930–941. DOI:10.1016/j.biopsych.2010.06.012.; Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., Lanctôt K.L. A meta-analysis of cytokines in major depression. Biol. Psychiatry. 2010; 67 (5): 446–457. DOI:10.1016/j.biopsych.2009.09.033.; Kim E.Y., Moudgil K.D. Immunomodulation of autoimmune arthritis by pro-inflammatory cytokines. Cytokine. 2017; 98: 87–96. DOI:10.1016/j.cyto.2017.04.012.; Gan W.Q., Man S.P., Senthilselvan A. et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004; 59 (7): 547–580. DOI:10.1136/thx.2003.019588.; Yang Y., Jing Z., Xin D., Wang S. Association between tumor necrosis factor-α and chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ther. Adv. Respir. Dis. 2019; 13: 1–4. DOI:10.1177/1753466619866096.; Mosrane Y., Bougrida M., Alloui A.S., Martani M., Rouabah L. Systemic inflammatory profile of smokers with and without COPD. Rev. Pneumol. Clin. 2017; 73 (4): 188–198. DOI:10.1016/j.pneumo.2017.07.003.; Jiang D.H., Wang X., Liu L.S. et al. The effect of ventilator mask atomization inhalation of ipratropium bromide and budesonide suspension liquid in the treatment of COPD in acute exacerbation period on circulating levels of inflammation and prognosis. Eur. Rev. Med. Pharmacol. Sci. 2017; 21 (22): 5211–5216. DOI:10.26355/eurrev_201711_13843.; Boraschi D., Tagliabue A. The interleukin-1 receptor family. Semin. Immunol. 2013; 25 (6): 394– 407. DOI:10.1016/j.smim.2013.10.023.; Rider P., Carmi Y., Guttman O., Braiman A., Cohen I., Voronov E., White M.R. et al. IL-1α and IL- 1β recruit different myeloid cells and promote different stages of sterile inflammation. J. Immunol. 2011; 187 (9): 4835–4843. DOI:10.4049/jimmunol.1102048.; Dinarello C.A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011; 117 (14): 3720–3732. DOI:10.1182/blood-2010-07-273417.; Cosio M.G., Majo J., Cosio M.G. Inflammation of the airways and lung parenchyma in COPD: role of T cells. Chest. 2002; 121 (5): 160–165. DOI:10.1378/chest.121.5_suppl.160s.; Pauwels N.S., Bracke K.R., Dupont L.L. et al. Role of IL-1alpha and the Nlrp3/caspase-1/IL-1beta axis in cigarette smoke-induced pulmonary inflammation and COPD. Eur. Respir. J. 2011; 38 (5): 1019–1028. DOI:10.1183/09031936.00158110.; Bafadhel M., McKenna S., Terry S. et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am. J. Respir. Crit. Care Med. 2011; 184 (6): 662–671. DOI:10.1164/rccm.201104-0597OC.; Zou Y., Chen X., Liu J., Zhou D.B., Kuang X., Xiao J., Yu Q. et al. Serum IL-1β and IL-17 levels in patients with COPD: Associations with clinical parameters. Int. J. Chronic Obstr. Pulm. Dis. 2017; 12: 1247–1254. DOI:10.2147/COPD.S131877.; Ozretić P., Filho P., Catalano C., Sokolović I., Vukić-Dugac A., Šutić M. Association of NLRP1 coding polymorphism with lung function and serum IL-1β concentration in patients diagnosed with chronic obstructive pulmonary disease (COPD). 2019; 10 (10): 783. DOI:10.3390/genes10100783.; Fragoso J.M., Delgadillo H., Juárez-Cedillo T., Rodríguez-Pérez J.M., Vallejo M., Pérez-Méndez O. et al. The interleukin 6 -572 G>C (rs1800796) polymorphism is associated with the risk of developing acute coronary syndrome. Genet. Test Mol. Biomarkers. 2010; 14 (6): 759–763. DOI:10.1089/gtmb.2010.0001.; Heinrich P.C., Behrmann I., Müller-Newen G., Schaper F., Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. The Biochemical Journal. 1998; 334 (2): 297–314. DOI:10.1042/bj3340297.; Tanaka T., Narazaki M., Kishimoto T. Il-6 in inflammation, immunity, and disease. Cold Spring Harb. Perspect. Biol. 2014; 6 (10): 1–4. DOI:10.1101/cshperspect.a016295.; Celli B.R., Locantore N., Yates J., Tal-Singer R., Miller B.E., Bakke P., Calverley P., Coxson H., Crim C. et al. ECLIPSE Investigators. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2012; 185 (10): 1065–1072. DOI:10.1164/rccm.201110-1792OC; Donaldson et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest. 2005; 128 (4):1995–2004. DOI:10.1378/chest.128.4.1995.; Garcia-Rio F., Miravitlles M., Soriano J.B., Munoz L., Duran-Tauleria E., Sanchez G., Sobradillo V., Ancochea J. Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respiratory Research. 2010; 11 (1): 63–77. DOI:10.1186/1465-9921-11-63.; Agusti A., Edwards L.D., Rennard S.I., MacNee W., Tal-Singer R., Miller B.E., Vestbo J. et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012; 7 (5): e37483. DOI:10.1371/journal.pone.0037483.; Wei J., Xiong X., Lin Y., Zheng B., Cheng D. Association between serum interleukin-6 concentrations and chronic obstructive pulmonary disease: a systematic review and meta-analysis. Peer J. 2015; 3: 1199. DOI:10.7717/peerj.1199.; Sabit R., Bolton C.E., Edwards P.H., Pettit R.J., Evans W.D., McEniery C.M. et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine. 2007; 175 (12): 1259–1265. DOI:10.1164/rccm.200701-067OC.; Van Helvoort H.A., Heijdra Y.F., Thijs H.M., Vina J., Wanten G.J., Dekhuijzen P.N. Exercise-induced systemic effects in muscle-wasted patients with COPD. Medicine and Science in Sports and Exercise. 2006; 38 (9): 1543–1552. DOI:10.1249/01.mss.0000228331.13123.53.; Zhang W., Chen H. The study on the interleukin-8. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2002; 19 (4): 697–702.; Hébert C.A., Baker J.B. Interleukin-8: a review. Cancer Invest. 1993; 11 (6): 743–750. DOI:10.3109/07357909309046949.; De Boer W.I., Sont J.K., van Schadewijk A., Stolk J., van Krieken J.H., Hiemstra P.S. Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD. J. Pathol. 2000; 190 (5): 619–626. DOI:10.1002/(SICI)1096-9896(200004)190:53.0.CO;2-6.; Govindaraju V., Michoud M.C., Al-Chalabi M., Ferraro P., Powell W.S., Martin J.G. Interleukin-8: novel roles in human airway smooth muscle cell contraction and migration. Am. J. Physiol. Cell Physiol. 2006; 291 (5): 957–965. DOI:10.1152/ajpcell.00451.2005.; Zhang J., Bai C. The significance of serum interleukin-8 in acute exacerbations of chronic obstructive pulmonary disease. Tanaffos. 2018; 17 (1): 13–21.; Samuel D., López-Vales R., Wee Yong V. Harmful and beneficial effects of inflammation after spinal cord injury: potential therapeutic implications. Handbook of Clinical Neurology. 2012; 109: 485–502. DOI:10.1016/B978-0-444-52137-8.00030-9.; Hector R., Wong J.E., Nowak-Stephen W., de Oliveira C.F. Sepsis. Pediatric Critical Care. 2011; 4: 1413–1429. DOI:10.1016/B978-0-323-07307-3.10103-X.; Pestka S., Krause C.D., Sarkar D., Walter M.R., Shi Y., Fisher P.B. Interleukin-10 and related cytokines and receptors. Ann. Rev. Immunol. 2004; 22: 929–979. DOI:10.1146/annurev.immunol.22.012703.104622.; McGeachy M.J., Bak-Jensen K.S., Chen Y., Tato C.M., Blumenschein W., Cua D.J. TGF-β and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain TH-17 cell-mediated pathology. Nat. Immunol. 2007; 8 (12): 1390–1397. DOI:10.1038/ni1539.; Spits H., De Waal M.R. Functional characterization of human IL-10. Int. Arch. Allergy Immunol. 1992; 99 (1): 8–15. DOI:10.1159/000236329.; Couper K.N., Blount D.G., Riley E.M. IL-10: The Master Regulator of Immunity to Infection. J. Immunol. 2008; 180 (9): 5771–5777. DOI:10.4049/jimmunol.180.9.5771.; LeVan T.D., Romberger D.J., Siahpush M., Grimm B.L. Relationship of systemic IL-10 levels with proinflammatory cytokine responsiveness and lung function in agriculture workers. Respir. Res. 2018; 19 (1): 166. DOI:10.1186/s12931-018-0875-z.; Zhang L., Cheng Z., Liu W., Wu K. Expression of interleukin (IL)-10, IL-17A and IL-22 in serum and sputum of stable chronic obstructive pulmonary disease patients. COPD. 2013; 10 (4): 459–465. DOI:10.3109/15412555.2013.770456.; Takanashi S., Hasegawa Y., Kanehira Y., Yamamoto K., Fujimoto K., Satoh K., Okamura K. Interleukin-10 level in sputum is reduced in bronchial asthma, COPD and in smokers. Eur. Respir. J. 1999; 14 (2): 309–314. DOI:10.1034/j.1399-3003.1999.14b12.x.; Moermans C., Heinen V., Nguyen M., Henket M., Sele J., Manise M., Corhay J.L., Louis R. Local and systemic cellular inflammation and cytokine release in chronic obstructive pulmonary disease. Cytokine. 2011; 56 (2): 298–304. DOI:10.1016/j.cyto.2011.07.010.; Figueiredo C.A., Barreto M.L., Alcantara-Neves N.M., Rodrigues L.C., Cooper P.J., Cruz A.A. et al. Coassociations between IL10 polymorphisms, IL-10 production, helminth infection, and asthma/wheeze in an urban tropical population in Brazil. J. Allergy Clin. Immunol. 2013; 131 (6): 1683–1690. DOI:10.1016/j.jaci.2012.10.043.; Bradford E., Jacobson S., Varasteh J., Comellas A.P., Woodruff P., O’Neal W., DeMeo D.L., Li X., Kim V., Cho M. et al. The value of blood cytokines and chemokines in assessing COPD. Respir. Res. 2017; 18 (1): 180. DOI:10.1186/s12931-017-0662-2.; Demeo D.L., Campbell E.J., Barker A.F., Brantly M.L., Eden E., McElvaney N.G. et al. IL10 polymorphisms are associated with airflow obstruction in severe alpha1-antitrypsin deficiency. Am. J. Respir. Cell Mol. Biol. 2008; 38 (1): 114–120. DOI:10.1165/rcmb.2007-0107OC.; Yoshimura T. The chemokine MCP-1 (CCL2) in the host interaction with cancer: a foe or ally? Cellular & Molecular Iimmunology. 2018; 15 (4): 335–345. DOI:10.1038/cmi.2017.135.; Batiushin M., Gadaborsheva K. Monocyte chemoattractant protein-1: its role in the development of tubulointerstitial fibrosis in nephropathies. Medical News of the North Caucasus. 2017; 2: 1–3.; Panee J. Monocyte chemoattractant protein 1 (MCP-1) in obesity and diabetes. Cytokine. 2012; 60 (1): 1–12. DOI:10.1016/j.cyto.2012.06.018.; Dean R.A., Cox J.H., Bellac C.L., Doucet A., Starr A.E., Overall C.M. Macrophage-specific metalloelastase (MMP-12) truncates and inactivates ELR+ CXC chemokines and generates CCL2, -7, -8, and -13 antagonists: potential role of the macrophage in terminating polymorphonuclear leukocyte influx. Blood. 2008; 112 (8): 3455–3464. DOI:10.1182/blood-2007-12-129080.; Di Stefano A., Coccini T., Roda E., Signorini C., Balbi B., Brunetti G., Ceriana P. Blood MCP-1 levels are increased in chronic obstructive pulmonary disease patients with prevalent emphysema. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 1691–1700. DOI:10.2147/COPD.S159915.; Traves S., Culpitt S., Russell R., Barnes P., Donnelly L. Increased levels of the chemokines GROα and MCP-1 in sputum samples from patients with COPD. Thorax. 2002; 57 (7): 590–595. DOI:10.1136/thorax.57.7.590.; De Boer W.I., Sont J.K., van Schadewijk A., Stolk J., van Krieken H., Hiemstra P.S. Monocyte chemoattractant protein 1, interleukin 8, and chronic airways in ammation in COPD. J. Pathol. 2000; 190 (5): 619–626. DOI:10.1002/(SICI)1096-9896(200004)190:53.0.CO;2-6.; Aldonyte R., Jansson L., Piitulainen E. Circulating monocytes from healthy individuals and COPD patients. Respir. Res. 2003; 4 (1): 11. DOI:10.1186/1465-9921-4-11.; Mimuro J. Type 1 plasminogen activator inhibitor: its role in biological reactions. The Japanese Journal of Clinical Hematology. 1991; 32 (5): 487–489.; Борисова Е.П., Кылбанова Е.С., Асекритова А.С. Клинико-генетические особенности сочетания хронического бронхита и хронической обструктивной болезни легких с метаболическим синдромом у якутов. Вестник Северо-Восточного федерального университета им. М.К. Аммосова. 2014; 11 (4): 1.; Lijnen H.R. Pleiotropic functions of plasminogen activator inhibitor‐1. Journal of Trombosis and Hemostasis. 2005; 3 (1): 35–45. DOI:10.1111/j.1538-7836.2004.00827.x.; Binder B.R., Christ G., Gruber F., Grubic N., Hufnagl P., Krebs M., Mihaly J., Prager G.W. Plasminogen activator inhibitor 1: physiological and pathophysiological roles. News in Physiological Sciences. 2002; 17: 56–61. DOI:10.1152/nips.01369.2001.; Berberoglu M., Evliyaoglu O., Adiyaman P. et al. Plasminogen activator inhibitor-1 (PAI-1) gene polymorphism (-675 4G/5G) associated with obesity and vascular risk in children. Pediatr. Endocrinol. Metab. 2006; 19 (5): 741–748. DOI:10.1515/jpem.2006.19.5.741.; Khavinson V.Kh., Strekalov D.L., Lyshchev A.A. et al. Association analysis of some genetic risk factors for coronary heart disease with indicators of lipid metabolism and arterial pressure. Kliniko-laboratornyi konsilium. 2010; 4: 52–53.; Wang H., Yang T., Li D. et al. Elevated circulating PAI-1 levels are related to lung function decline, systemic inflammation, and small airway obstruction in chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 2016; 11: 2369–2376. DOI:10.2147 / COPD.S107409.; Essa E.S., Wahsh R.A. Association between plasminogen activator inhibitor-1-675 4G/5G insertion/deletion polymorphism and chronic obstructive pulmonary disease. COPD. 2016; 13 (6): 756–775. DOI:10.3109/15412555.2016.1168392.; Waschki B., Watz H., Holz O., Magnussen H., Olejnicka B., Welte T., Rabe K.F., Janciauskiene S. Plasminogen activator inhibitor-1 is elevated in patients with COPD independent of metabolic and cardiovascular function. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; 12: 981–987. DOI:10.2147/COPD.S128689.; Muller Y.A., Ultsch M.H., de Vos A.M. The crystal structure of the extracellular domain of human tissue factor refined to 1.7. Journal of Molecular Biology. 1996; 256 (1): 144–459. DOI:10.1006/jmbi.1996.0073.; Zhang E., Charles R., Tulinsky A. Structure of extracellular tissue factor complexed with factor VIIa inhibited with a BPTI mutant. Journal of Molecular Biology.1999; 285 (5): 2089–2104. DOI:10.1006/jmbi.1998.2452.; Ruf W., Disse J., Carneiro-Lobo T.C., Yokota N., Schaffner F. Tissue factor and cell signalling in cancer progression and thrombosis. Journal of Thrombosis and Haemostasis. 2011; 9 (1): 306–315. DOI:10.1111/j.1538-7836.2011.04318.x.; Szotowski B., Antoniak S., Poller W. et al. Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. Circ. Res. 2005; 96 (12): 1233–1239. DOI:10.1161/01.RES.0000171805.24799.fa.; Davizon P., Lopez J.A. Microparticles and thrombotic disease. Curr Opin Hematol. 2009; 16(5): 334–341. DOI:10.1097/MOH.0b013e32832ea49c.; Osterud B., Bjorklid E. Sources of tissue factor. Semin. Thromb. Hemost. 2006; 32 (1): 11–23. DOI:10.1055/s-2006-933336.; Peshkova A.D., Le Minh G., Tutwiler V. et al. Activated monocytes enhance platelet-driven contraction of blood clots via tissue factor expression. Sci. Rep. 2017; 7 (1): 5149. DOI:10.1038/s41598-017-05601-9.; Chiva-Blanch G., Laake K., Myhre P. et al. Platelet-, monocyte- derived and tissue factor- carrying circulating microparticles are related to acute myocardial infarction severity. PLoS One. 2017; 12 (2): 1–3. DOI:10.1371/journal.pone.0172558.; Leatham E.W., Bath P.M., Tooze J.A. et al. Increased monocyte tissue factor expression in coronary disease. Br. Heart J. 1995; 73 (1): 10–13. DOI:10.1136/hrt.73.1.10.; Shantsila E., Lip G.Y. The role of monocytes in thrombotic disorders. Insights from tissue factor, monocyte-platelet aggregates and novel mechanisms. Thromb. Haemost. 2009; 102(5): 916–924. DOI:10.1160/TH09-01-0023; Brambilla M., Facchinetti L., Canzano P. et al. Human megakaryocytes confer tissue factor to a subset of shed platelets to stimulate thrombin generation. Thromb. Haemost. 2015; 114 (3): 579–592. DOI:10.1160/TH14-10-0830; Darbousset R., Thomas G.M., Mezouar S. et al. Tissue factor-positive neutrophils bind to injured endothelial wall and initiate thrombus formation. Blood. 2012; 120 (10): 2133–2143. DOI:10.1182/blood-2012-06-437772; De Palma R., Cirillo P., Ciccarelli G. et al. Expression of functional tissue factor in activated T-lymphocytes in vitro and in vivo: A possible contribution of immunity to thrombosis? Int. J. Cardiol. 2016; 218: 188–195. DOI:10.1016/j.ijcard.2016.04.177; Vaidyula V.R., Criner G.J., Grabianowski C., Rao A.K. Circulating tissue factor procoagulant activity is elevated in stable moderate to severe chronic obstructive pulmonary disease. Thromb. Res. 2009; 124 (3): 259–261 DOI:10.1016/j.thromres.2008.12.030; Jankowski M., Undas A., Kaczmarek P., Butenas S. Activated factor XI and tissue factor in chronic obstructive pulmonary disease: links with inflammation and thrombin generation. Thromb. Res. 2011; 127(3): 242–246. DOI:10.1016/j.thromres.2010.11.005.; Undas A., Jankowski M., Kaczmarek P., Sladek K., Brummel‐Ziedins K. Thrombin generation in chronic obstructive pulmonary disease: dependence on plasma factor composition. Thromb. Res. 2011; 128(4): 24–28. DOI:10.1016/j.thromres.2011.05.004.; Szczypiorska A., Czajkowska-Malinowska M., Góralczyk B. Tissue factor and tissue factor pathway inhibitor in chronic obstructive pulmonary disease. Folia Medica Copernicana. 2015; 3 (1): 32–37.; Go A.S., Chertow G.M., Fan D. et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 2004; 351(13): 1296–1305. DOI:10.1056/NEJMoa041031.; Дранник Г.Н., Майданник В.Г. Роль системы комплемента в физиологических и патологических реакциях организма. Врачебное дело. 1989; (4): 69–73.; Maidannyk V.G., Bohomolets A.A. The complement system and complement-mediated injury of kidney disease in children. International Journal of Рediatric, Obstetric and Gynecology. 2013; 49 (1): 119–134.; Holers V.M. Complement and its receptors: new insights into human disease. Annu. Re.v Immunol. 2014; 32: 433–459. DOI:10.1146/annurev-immunol-032713-120154.; Abbas A.K., Lichtman A.H., Pillai S. Cellular and molecular. Immunology. 2010; 6: 272–288.; Serna M., Giles J.L., Morgan B.P., Bubeck D. Structural basis of complement membrane attack complex formation. Nature Communications Pediatric Hematology/Oncology and Immunopathology. 2016; 7: 10587. DOI:10.1038/ncomms10587.; Héja D., Kocsis A., Dobó J., Szilágyi K., Szász R., Závodszky P., et al. Revised mechanism of complement lectin-pathway activation revealing the role of serine protease MASP-1 as the exclusive activator of MASP-2. PNAS USA. 2012; 109(26): 10498–10503. DOI:10.1073/pnas.1202588109.; Ferreira V.P., Pangburn M.K., Cortés C. Complement control protein factor H: The good, the bad, and the inadequate. Mol Immunol. 2010; 47 (13): 2187–2197. DOI:10.1016/j.molimm.2010.05.007.; Strunk R.C., Eidlen D.M., Mason R.J. Pulmonary alveolar type ii epithelial cells synthesize and secrete proteins of the classical and alternative complement pathways. J Clin. Invest. 1988; 81: 1419–1426. DOI:10.1172/JCI113472.; Varsano S., Kaminsky M., Kaiser M., Rashkovsky L. Generation of complement c3 and expression of cell membrane complement inhibitory proteins by human bronchial epithelium cell line. Thorax. 2000; 55 (5): 364–369. DOI:10.1136/thorax.55.5.364.; Volanakis J.E. Transcriptional regulation of complement genes. Annu Rev Immunol. 1995; 13: 277–305. DOI:10.1146/annurev.iy.13.040195.001425.; Westwood J.P., Mackay A., Donaldson G., Machin S., Wedzicha J.A., Scully M. The role of complement activation in COPD exacerbation recovery. ERJ Open Res. 2016; 2 (4): 27. DOI:10.1183/23120541.00027-2016.; Chauhan S., Gupta M.K., Goyal A., Dasgupta D.J. Alterations in immunoglobulin and complement levels in chronic obstructive pulmonary disease. Indian. J. Med. Res. 1990; 92: 241-245.; Mahesh M., Yalamudi M., Lokesh S. Complement levels in chronic obstructive pulmonary disease: correlation with pulmonary function and radiological emphysema score. International Journal of Scientific Study. 2016; 3 (12): 284.; Kew R.R., Ghebrehiwet B., Janoff A. Cigarette smoke can activate the alternative pathway of complement in vitro by modifying the third component of complement. J. Clin. Invest. 1985; 75 (3): 1000–1007. DOI:10.1172/JCI111760.; Floreani A.A., Wyatt T.A., Stoner J., Sanderson S.D., Thompson E.G., Allen-Gipson D., Heires A.J. Smoke and c5a induce airway epithelial intercellular adhesion molecule-1 and cell adhesion. Am. J. Respir. Cell Mol. Biol. 2003; 29 (4): 472–448. DOI:10.1165/rcmb.2002-0143OC; Grumelli S., Lu B., Peterson L., Maeno T., Gerard C. Cd46 protects against chronic obstructive pulmonary disease. PLoS ONE. 2011; 6 (5): 18785. DOI:10.1371/journal.pone.0018785.; https://bulletin.tomsk.ru/jour/article/view/4391
-
19Academic Journal
Συγγραφείς: Friptu, V.G., Фрипту, В.Г., Oleinic, V.F., Олейник, В.Ф.
Πηγή: Buletin de Perinatologie 92 (3) 8-11
Θεματικοί όροι: preeclampsia, biochemical markers, HIF, преэклампсия, биохимические маркеры
Περιγραφή αρχείου: application/pdf
Relation: https://ibn.idsi.md/vizualizare_articol/150113; urn:issn:18105289
Διαθεσιμότητα: https://ibn.idsi.md/vizualizare_articol/150113
-
20Academic Journal
Συγγραφείς: A. V. Mitronin, O. A. Khvorostenko, D. A. Ostanina, Yu. A. Mitronin
Πηγή: Эндодонтия Today, Vol 19, Iss 3, Pp 171-174 (2021)
Θεματικοί όροι: ротовая жидкость, биохимические маркеры, неинвазивная диагностика, экспрессдиагностика, протеом, Dentistry, RK1-715
Relation: https://www.endodont.ru/jour/article/view/1002; https://doaj.org/toc/1683-2981; https://doaj.org/toc/1726-7242; https://doaj.org/article/63fd8f5801d2422486215b688bbc1c16